AstraZeneca PLC (AZN) Gains After Successful Saphnelo Trial

We recently compiled a list of the Top 10 Oncology Stocks to Buy Now. AstraZeneca PLC is placed fourth on our list among the best cancer stocks.

TheFly reported on January 6 that Barclays analyst James Gordon increased the price target on AZN to 16,500 GBp from 14,000 GBp. The firm maintained an Overweight rating on the shares.

On the same day, AstraZeneca announced statistically significant results from its Phase III TULIP‑SC trial of Saphnelo (anifrolumab) in systemic lupus erythematosus (SLE). Subcutaneous self-administration of Saphnelo led to a clinically significant reduction in disease activity at Week 52, with 56.2% of patients showing improvement as opposed to 37.1% in the placebo group. These results support saphnelo’s potential as an SLE therapy.

AstraZeneca PLC (NASDAQ:AZN) is a global biopharmaceutical company advancing cancer care through a robust late-stage oncology pipeline, innovative targeted therapies, and immuno-oncology treatments, aiming to improve patient outcomes across multiple tumor types worldwide.

While we acknowledge the potential of AZN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 12 Best Multibagger Stocks to Buy Heading into 2026 and 7 Best Rising Tech Stocks to Buy Now.

Disclosure: None.